REFORM study: Reviewing Effects of Vildagliptin-Dapagliflozin FDC on HbA1c & Weight in Type 2 Diabetes Management
Written By : Dr. Nandita Mohan
Published On 2025-01-17 06:30 GMT | Update On 2025-01-17 10:57 GMT
The fixed-dose combination (FDC) of Vildagliptin 1000mg SR and Dapagliflozin 10mg showed significant glycemic control, weight reduction, and favorable safety outcomes in managing Type 2 Diabetes (T2D) in a recent study published in the July 2024 edition of the Journal of Medicine and Healthcare has concluded.
This retrospective analysis evaluated data from 1587 T2D patients prescribed vildagliptin dapagliflozin FDC, with two follow-up visits over a six-month period. It included 1,587 records from 72 centers, with patients of an average age of 55.8 years. Patients were grouped by diabetes duration and baseline HbA1c levels (less than 7%, 7-8%, 8-9%, greater than or equal to 9%).
Some of the Key Findings of the study are:
1. Glycemic Control: After six months of therapy, patients experienced an average HbA1c reduction of 1.28%. Among those with baseline HbA1c greater than 7%, 67.2% achieved the target HbA1c of less than 7%. The most substantial improvement was observed in patients with HbA1c greater than or equal to 9%, who experienced a reduction of 2.0%, while reductions were 0.8% in the HbA1c 7–8% group and 1.1% in the HbA1c 8–9% group.
2. Weight Reduction: The highest weight reduction 4.9 kg was observed in those with baseline HbA1c ≥9%, with an overall average weight loss of 4.3 kg across all groups.
3. Safety Profile: The FDC was well-tolerated, with no major adverse events or episodes of hypoglycemia reported. No patient withdrawals were attributed to safety concerns. Vildagliptin 100mg SR + Dapagliflozin 10mg FDC showed to be an effective treatment for T2D, given its synergistic capacity to help achieve glycemic targets while offering benefits like weight reduction and improved liver enzymes.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.